Stock Track | Recursion Pharma's Stock Plunges on Q3 Revenue Shortfall

Stock Track11-07

Recursion Pharmaceuticals, Inc. (RXRX) experienced a pre-market plunge of 6.17% on Wednesday, November 7, following the release of its third-quarter earnings results. While the biotech company beat earnings estimates, reporting a loss of $0.34 per share versus the expected $0.37 loss, its revenue fell short of analysts' expectations.

For the quarter ended September 30, Recursion reported revenue of $26.1 million, significantly lower than the $34.7 million consensus forecast from analysts polled by Zacks. Despite representing a 147.6% increase from the prior-year quarter, the revenue miss weighed heavily on investor sentiment, leading to the significant pre-market decline.

Analysts from TD Cowen maintained a "Hold" rating on Recursion Pharmaceuticals' stock following the earnings release, highlighting the importance of revenue growth for the company's future prospects. The biotechnology sector heavily relies on consistently increasing revenue streams to fund research and development efforts, making revenue performance a crucial factor for investor confidence.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1111622401?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-07 17:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111622401","market":"hk","top_or_hot":-1,"title":"Stock Track | Recursion Pharma's Stock Plunges on Q3 Revenue Shortfall","media":"Stock Track","content":"<p>Recursion Pharmaceuticals, Inc. (RXRX) experienced a pre-market plunge of 6.17% on Wednesday, November 7, following the release of its third-quarter earnings results. While the biotech company beat earnings estimates, reporting a loss of $0.34 per share versus the expected $0.37 loss, its revenue fell short of analysts' expectations.</p>\n\n<p>For the quarter ended September 30, Recursion reported revenue of $26.1 million, significantly lower than the $34.7 million consensus forecast from analysts polled by Zacks. Despite representing a 147.6% increase from the prior-year quarter, the revenue miss weighed heavily on investor sentiment, leading to the significant pre-market decline.</p>\n\n<p>Analysts from TD Cowen maintained a \"Hold\" rating on Recursion Pharmaceuticals' stock following the earnings release, highlighting the importance of revenue growth for the company's future prospects. The biotechnology sector heavily relies on consistently increasing revenue streams to fund research and development efforts, making revenue performance a crucial factor for investor confidence.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Recursion Pharma's Stock Plunges on Q3 Revenue Shortfall</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Recursion Pharma's Stock Plunges on Q3 Revenue Shortfall\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-07 17:04 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Recursion Pharmaceuticals, Inc. (RXRX) experienced a pre-market plunge of 6.17% on Wednesday, November 7, following the release of its third-quarter earnings results. While the biotech company beat ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RXRX","symbol_name":"Recursion Pharmaceuticals, Inc.","start_time":0,"source_url":"","article_id":"1111622401","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111622401","pubTimestamp":1730970275,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Recursion Pharmaceuticals, Inc.  experienced a pre-market plunge of 6.17% on Wednesday, November 7, following the release of its third-quarter earnings results. While the biotech company beat earnings estimates, reporting a loss of $0.34 per share versus the expected $0.37 loss, its revenue fell short of analysts' expectations.For the quarter ended September 30, Recursion reported revenue of $26.1 million, significantly lower than the $34.7 million consensus forecast from analysts polled by Zack","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RXRX":"Recursion Pharmaceuticals, Inc."},"translate_title":"股票追踪Recursion Pharma股价因第三季度收入短缺而暴跌","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RXRX":1},"content_text":"Recursion Pharmaceuticals, Inc. (RXRX) experienced a pre-market plunge of 6.17% on Wednesday, November 7, following the release of its third-quarter earnings results. While the biotech company beat earnings estimates, reporting a loss of $0.34 per share versus the expected $0.37 loss, its revenue fell short of analysts' expectations.\nFor the quarter ended September 30, Recursion reported revenue of $26.1 million, significantly lower than the $34.7 million consensus forecast from analysts polled by Zacks. Despite representing a 147.6% increase from the prior-year quarter, the revenue miss weighed heavily on investor sentiment, leading to the significant pre-market decline.\nAnalysts from TD Cowen maintained a \"Hold\" rating on Recursion Pharmaceuticals' stock following the earnings release, highlighting the importance of revenue growth for the company's future prospects. The biotechnology sector heavily relies on consistently increasing revenue streams to fund research and development efforts, making revenue performance a crucial factor for investor confidence.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1111622401"}